摘要
目的优化表达人肿瘤坏死因子受体Ⅱ-Fc(TNFR-Fc)融合蛋白的重组CHO-DG44细胞的培养温度,并考察该细胞株在最佳温度放大培养下纯化后的产物纯度及活性。方法采用批次培养方式,将重组中国仓鼠卵巢细胞培养于37℃、37℃转31℃、31℃3种不同的温度下,每日取样检测细胞密度、细胞活率、葡萄糖浓度、乳酸浓度、人肿瘤坏死因子受体Ⅱ-Fc融合蛋白浓度,并选择最佳的培养温度对重组中国仓鼠卵巢细胞进行放大(10、50、200 mL、2 L)培养,所得培养上清经Protein A亲和色谱柱纯化,并采用SDS-PAGE,SE-HPLC,WST-8对人肿瘤坏死因子受体Ⅱ-Fc融合蛋白进行相对分子质量,纯度和生物活性检测。结果研究发现,37℃转31℃的转温度培养条件可在保持高密度活细胞的同时维持细胞活率,延长培养周期,显著提高人肿瘤坏死因子受体Ⅱ-Fc融合蛋白产量,并且该转温度培养工艺可成功地应用于重组CHO细胞的规模放大培养中。纯化后的人肿瘤坏死因子受体Ⅱ-Fc融合蛋白相对分子质量约为150×103,纯度在93%以上,生物活性检测显示其可中和重组人肿瘤坏死因子α的细胞毒效应。结论相比单一的37℃培养条件,37℃转31℃的转温度培养工艺可明显提高重组CHO-DG44细胞的人肿瘤坏死因子受体Ⅱ-Fc融合蛋白表达量,且该工艺具有可放大性,这为该工艺的更大规模应用奠定了基础。
OBJECTIVE To optimize the culture temperature of recombinant CHO-DCA4 cells expressing tumor necrosis factor receptor-Fc fusion protein and to determine the bioactivity of expressed protein at the best culture temperature. METHODS Recombinant CHO cells were batchly cultured at three different temperatures (37 ℃ ,37 ℃ shifting to 31℃ and 31 ℃ ). Samples were daily tested for cell densities, viabilities, glucose concentration, lactic acid concentration and TNFR-Fc fusion protein concentration, then the best culture temperature was chosen to scale up the fermentation volume( 10, 50,200 mL, and 2 L). TNFR-Fc fusion protein was purified with Protein A affinity chromatography, determined for relative molecular mass, purity and neutralizing activity by SDS-PAGE, SE-HPLC and WST-8 separately. RESULTS The culture condition of 37℃ shifting to 31℃ resulted in the maximum viable cell density, high viability and long culture time of the cells as well as high TNFR-Fc protein productivity, and this culture procedure could be successfully applied to the scale-up of recombinant CHO cells. The purified fusion protein, with a relative molecular mass about 150 000, reached the purity of more than 93% and neutralized the eytotoxic effect of TNFa. CONCLUSION Compared to the traditional culture temperature of 37 ℃ ,the culture temperature of 37℃ shifting to 31℃ can obviously improve the TNFR-Fc fusion protein output by recombinant CHO-DG44 cells. And this technique ean be applied to scale-up, which will lay a foundation of large scale industrial production.
出处
《中国药学杂志》
CAS
CSCD
北大核心
2013年第2期90-96,共7页
Chinese Pharmaceutical Journal
基金
国家重大新药创制资助项目(2012ZX09103301-033
2012ZX09202301)
暨南大学科研培育与创新基金杰出人才培育资助项目(1161-1206)
抗体规模制备技术及肿瘤抗体药物的研究(2010U1-E00541)